Stocktoria
Vistagen Therapeutics, Inc. VTGN
Vistagen Therapeutics, Inc. (VTGN) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2026 revenue was $1.3M at a -5491.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VTGN | Vistagen Therapeutics, Inc. | 2/9 | — | — | — |
| IGC | IGC Pharma, Inc. | 3/9 | — | — | — |
| LGVN | Longeveron Inc. | 2/9 | — | — | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
| SXTC | China SXT Pharmaceuticals, Inc. | 3/9 | 2.19 | — | — |
| RNXT | RenovoRx, Inc. | 2/9 | — | — | — |
| NRXP | NRX Pharmaceuticals, Inc. | 4/9 | — | — | — |
About Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
FAQ
Is VTGN financially healthy?
Vistagen Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does VTGN pay a dividend?
No, Vistagen Therapeutics, Inc. does not currently pay a dividend.
How profitable is VTGN?
In FY2026, Vistagen Therapeutics, Inc. had a net margin of -5491.3% and a return on equity of -196.2%.
What is the analyst price target for VTGN?
The average Wall-Street price target for Vistagen Therapeutics, Inc. is $1.00, about 282.8% above the recent price, from 2 analysts (consensus: hold).
Is VTGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Vistagen Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.